Pharmaphorum
The FDA has started a priority review of Sanofi’s brain-acting Gaucher disease therapy venglustat, with an action date of 25th November.
Pharmaphorum
The FDA has started a priority review of Sanofi's brain-acting Gaucher disease therapy venglustat, with an action date of 25th November.
Pharmaphorum
The FDA has started a priority review of Sanofi’s brain-acting Gaucher disease therapy venglustat, with an action date of 25th November.